Stock Screener App

Frei -

Installieren

258.13

4.74% -12.85

Praxis Precision Medicines Inc (PRAX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten

Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - Seeking Alpha

PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus

Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative

Praxis Precision Medicines announces alignment with FDA - marketscreener.com

PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus

Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan

Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Praxis Precision Medicines, Inc. $PRAX Shares Bought by Swiss National Bank - MarketBeat

Praxis Precision Medicine (PRAX): Guggenheim Raises Price Target to $760 | PRAX Stock News - GuruFocus

Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN

Praxis Precision Medicines, Inc. $PRAX Stock Holdings Boosted by B Group Inc. - MarketBeat

Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat

Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins - Insider Monkey

BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN

PRAX Stock Surge: Rally or Risk? - StocksToTrade

Praxis Precision Medicines reports clinical updates on epilepsy drug candidates - Investing.com Nigeria

Praxis Precision Medicines Shares RADIANT Study Results - TipRanks

TD Cowen Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq

PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Finviz

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $353.00 - MarketBeat

TD Cowen Raises Price Target for PRAX to $353, Maintains Buy Rat - GuruFocus

Truist Securities Raises Price Target for PRAX to $500 | PRAX St - GuruFocus

Praxis Precision Medicines (NASDAQ:PRAX) Given New $500.00 Price Target at Truist Financial - MarketBeat

Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat

Needham raises Praxis Precision Medicines stock price target on improved data - Investing.com Nigeria

Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen - Investing.com UK

Truist Securities raises Praxis Precision Medicines stock price target to $500 - Investing.com Nigeria

Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data By Investing.com - Investing.com South Africa

PRAX Releases Promising Clinical Updates on Epilepsy Treatments - GuruFocus

Praxis Precision Medicine (PRAX) Sees Raised Price Target by Nee - GuruFocus

Needham & Company LLC Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat

Praxis Precision Medicines Reports Positive EMBOLD and RADIANT Study Results for Relutrigine and Vormatrigine in Epilepsy Treatment - Quiver Quantitative

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies - The Manila Times

Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating - marketscreener.com

HC Wainwright Reiterates 'Buy' Rating on PRAX with $340 PT | PRA - GuruFocus

Praxis (NASDAQ: PRAX) posts 53% seizure drop in EMBOLD trial, plans FDA NDA talks - Stock Titan

Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data - Investing.com Australia

BTIG Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq

PRAX: BTIG Raises Price Target to $507 with Buy Rating | PRAX St - GuruFocus

Praxis Precision Medicines (PRAX) Gaining Confidence on EMBOLD Study Optimism - Insider Monkey

Kennedy Capital Management LLC Increases Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week HighWhat's Next? - MarketBeat

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail

Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone - Yahoo Finance

Capital Fund Management S.A. Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Praxis Precision Medicine (PRAX) Target Price Raised by HC Wainw - GuruFocus

Praxis Precision Medicines stock hits 52-week high at $241.0 By Investing.com - Investing.com Nigeria

HC Wainwright & Co. maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN

Praxis Potential Breakthrough: Market Reactions - StocksToTrade

Another Praxis win provides much-needed progress in rare genetic epilepsies - BioCentury

PRAX Announces Breakthroughs in Neurological Treatments: Key Developments with FDA - StocksToTrade

Will Praxis Stock Climb Higher? - timothysykes.com

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle - BioWorld MedTech

Praxis Drug Trials Spark Optimism Amid Market Expansion - timothysykes.com

Praxis Precision Medicines Lights Up with Promising FDA Progress - timothysykes.com

How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story - Yahoo Finance

Uptick in Praxis Precision Medicines: What’s Next? - StocksToTrade

RPRX

$38.09

1.50%

INCY

$95.16

1.59%

GMAB

$30.93

3.16%

BNTX

$95.85

1.47%

ONC

$318.69

2.39%

INSM

$194.17

1.21%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters